Actavis will acquire Auden Mckenzie for approximately £306 million, or $460.6 million, in cash as well as a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products.
Actavis is a global specialty pharmaceutical company, with products addressing diseases in the central nervous system, gastroenterology and women's health. Auden Mckenzie is a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the United Kingdom. The acquisition will make Actavis the number one supplier of generic pharmaceuticals in the U.K.
This is the second acquisition announcement by Actavis in the last three months. The company said it would acquire Allergan, a Botox maker, for $66 billion in November.
More articles on GI/endoscopy:
Atlanta Gastroenterology Associates adds 4 physicians
enGene raises $11.5M for intestinal gene delivery platform development
Fujifilm's ground breaking technology